z-logo
Premium
Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression
Author(s) -
Basset Marco,
Hummedah Kamal,
Kimmich Christoph,
Veelken Kaya,
Dittrich Tobias,
Brandelik Simone,
Kreuter Michael,
Hassel Jessica,
Bosch Nikolaus,
StuhlmannLaeisz Christiane,
Blank Norbert,
MüllerTidow Carsten,
Röcken Christoph,
Hegenbart Ute,
Schönland Stefan
Publication year - 2020
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25915
Subject(s) - amyloidosis , medicine , concomitant , lung , immunoglobulin light chain , al amyloidosis , gastroenterology , clone (java method) , pathology , antibody , immunology , biology , dna , genetics
In localized light chain amyloidosis (locAL), amyloidogenic light chains (aLC) are produced and deposited locally by a B‐cell clone. We present 293 patients with immunohistochemically confirmed locAL. Lung (nodular pulmonary) with 63 patients was the most involved organ. The aLC was λ in 217 cases (κ:λ ratio 1:3). A local B‐cell clone was identified in 30% of cases. Sixty‐one (21%) had a concomitant autoimmune disorder (cAD). A monoclonal component (MC) were present in 101 (34%) patients and were more frequent in subjects with cAD (51% vs 34%; P = .03). Cigarette smoking was more prevalent in lung locAL (54% vs 37%; P = .018). After a median follow‐up of 44 months, 16 patients died and 5‐ and 10‐years locAL progression‐free survival (PFS) were 62% and 44%. Interestingly, locAL‐PFS was shorter among patients with an identified clonal infiltrate at amyloid deposition site (40 vs 109 months; P = .02) and multinuclear giant cells and/or an inflammatory infiltrate resulted in longer locAL‐PFS in lung involvement (65 vs 42 months; P = .01). However, no differences in locAL PFS were observed in patients with cAD, a MC and involved organ site. Treatment was administered in 163 (54%) patients and was surgical in 135 (46%). Median locAL‐PFS after first treatment was 56 months. Responders had longer locAL‐PFS (78 vs 17 months; P < .001). Three patients with lung locAL and a MC were diagnosed as systemic AL amyloidosis at follow‐up. In summary, locAL pathogenesis seems to be heterogeneous and the clonal infiltrate leads local progression.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here